marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-14-2024
Protalix BioTherapeutics Cash and Cash Equivalents 2011-2024 | PLX
Annual Cash and Cash Equivalents Protalix BioTherapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.6 M | 17.1 M | 39 M | 18.3 M | 17.8 M | 37.8 M | 51.2 M | 63.3 M | 76.4 M | 54.8 M | 86.4 M | 52 M | 27 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 86.4 M | 17.1 M | 43.4 M |
Quarterly Cash and Cash Equivalents Protalix BioTherapeutics
| 2024-Q3 | 2024-Q2 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.4 M | 23.4 M | 20.4 M | 48.2 M | 33 M | 17.1 M | 10.7 M | 12.5 M | 16.9 M | 39 M | 10.6 M | 33.9 M | 19.8 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 51.2 M | 51.2 M | 51.2 M | 51.2 M | 63.3 M | 63.3 M | 63.3 M | 63.3 M | 76.4 M | 76.4 M | 76.4 M | 76.4 M | 54.8 M | 54.8 M | 54.8 M | 54.8 M | 86.4 M | 86.4 M | 86.4 M | 86.4 M | 52 M | 52 M | 52 M | 52 M | 27 M | 27 M | 27 M | 27 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 86.4 M | 10.6 M | 42.5 M |